Yonsei Med J.
1994 Mar;35(1):91-96. 10.3349/ymj.1994.35.1.91.
GM-CSF and low-dose araC treatment of AML in prolonged hypoplasia with residual leukemic cells after induction chemotherapy
- Affiliations
-
- 1Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
- KMID: 1381222
- DOI: http://doi.org/10.3349/ymj.1994.35.1.91
Abstract
- We describe a case with acute myelogenous leukemia (AML; M2) who developed prolonged marrow hypoplasia with residual leukemic blasts and recurrent infections after induction chemotherapy. He was treated successfully with a sequential treatment of recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) and low-dose cytosine arabinoside (LD AraC). To the best of our knowledge this is the first reported case of a successful treatment of a patient with AML, who showed prolonged markedly hypocellular bone marrow with significant residual leukemic cells after induction chemotherapy, with a sequential treatment of GM-CSF and LD AraC.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Generation of Leukemic Dendritic Cells from Patients with Acute Myelogenous Leukemia
- A complete remission can be achieved despite persistence of abnormal bone marrow promyelocytes in acute promyelocytic leukemia: experience in 2 patients
- Differential responses of CD34-positive acute myelogenous leukemic blasts to the costimulating effects of stem cell factor with GM-CSF and/or IL-3
- Effect of GM-CSF to the M-VAC Chemotherapy Induced Leukopenia in Patients with Urothelial Cancer
- Immune Tolerance Effect of Immature Dendritic Cells Cultured Using Low-dose GM-CSF
